Ora, Inc., a US-based ophthalmology contract research organisation (CRO), has announced a strategic, exclusive partnership with the Singapore Eye Research Institute (SERI), a world-renowned institution for cutting-edge eye research and ophthalmic preclinical studies.

This exclusive partnership marks a significant milestone in the ophthalmology research industry by combining the unparalleled clinical development expertise of Ora with the cutting-edge preclinical study capabilities of SERI.

Aimed at providing early-stage innovators around the world with comprehensive research support, this partnership is set to revolutionise the development of new ophthalmic therapies.

With a reputation for excellence and a commitment to scientific rigor and ethical preclinical operations, SERI will collaborate with Ora’s biopharmaceutical and device clients to accelerate the development of therapeutic candidates across a range of ocular-specific therapeutic areas.

The partnership with SERI facilitates the efficient evaluation of potential therapeutic candidates for eye disorders, with expedited access to world class expertise and capabilities for preclinical evaluations.

This serves as a catalyst for Ora's expansion of research offerings, granting clients access to an even broader range of services to support their ophthalmic drug development programmes along with a heightened level of expertise and resources.